Despite widespread distribution of hepatitis B virus (HBV)-genotype D, the clinical implications of its ten subgenotypes (D1-D10) have not been well documented. Here, we have investigated the impact of two major circulating HBV/D subgenotypes, D1 and D3 in Eastern India towards pathogenesis of liver disease progression to hepatocellular carcinoma (HCC). HBV subgenotypes were determined using full-length genome sequences of HBV isolates from patients with chronic hepatitis B (CHB), liver cirrhosis (LC) and HCC. Impact of D1 and D3 on viral lifecycle and disease progression was assessed by several in vitro assays. Phylogenetic tree analysis revealed that HBV/D1 and HBV/D3 were the two predominating HBV subgenotypes circulating in Eastern India. Interestingly, the frequency of patients infected with HBV/D1 was noticed progressively rising from CHB to HCC through LC while the increasing frequency of HBV/D3 declined suddenly in HCC implicating HBV/D1 might have greater oncogenic potential than HBV/D3. Similar to higher viral load noted in HCC patients infected with HBV/ D1 than HBV/D3, the larger amount of intracellular/extracellular viral DNA and secreted HBsAg levels in transfected cell lines also implicated that HBV/D1 might replicate faster than HBV/D3. Again, higher expression of marker genes related to endoplasmic reticulum stress, epithelial-mesenchymal transition, DNA double strand breaks, angiogenesis etc. and faster rate of cellular migration and anchorage independent growth cumulatively suggested that compared to HBV/D3, HBV/D1 generates more liver injuries which eventually culminates into HCC. Therefore, our results highlight the importance of determination of subgenotypes of HBV in CHB patients, so that high-risk individual can be monitor periodically that may help to detect HCC at early stages.
Introduction
Chronic hepatitis B (CHB) is one of the major risk factors for the development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) worldwide (1, 2) . These are the final clinical consequences of decades of repetitive episodes of hepatitis B virus (HBV) infection into the hepatocytes, host-immune response, injury, repair and regeneration. Thus, the clinical course and the disease severity are governed by various factors including host immune mediated defense against viral pathogens followed by immune tailored selection pressure and viral biogeography (3) . Among these, viral genotype/subgenotype contributes considerably to the differences in geographical distribution of the virus, disease progression, transmission routes, disease outcomes and response to the antiviral therapeutics (4-7).
Phylogenetic and evolutionary analyses with the sequences of the surface region of HBV from different geographical regions have led to the classification of 10 distinct genotypes of HBV (A-J) based on intergroup diversity of greater than 7.5% while intra-group sequence dissimilarities in the full-length (FL) genome of 4-7.5% segregated most of the genotypes into multiple subgenotypes (8, 9) . It is clearly evident from several in vitro analyses of intracellular and extracellular DNA level of HBV and amount of viral antigens that HBV genotypes play a key role in disease pathogenesis, e.g. genotype B and C cause more severe cellular damages than genotype A and D (10, 11) . In Japan, Korea and China HBV genotype C is observed among older HCC patients (>40 years), whereas genotype B is observed in patients with non-cirrhotic HCC or with recurring HCC after surgical treatment (12) (13) (14) .
While, few studies on HBV subgenotypes have revealed that HBV/C2 (15) (16) (17) , B2-5 (9, 18) and F1 (9) are responsible for rapid HCC development and B2 is linked with faster progression to HCC without cirrhosis (19, 20) ; B1, B6 and A2 are reported to be allied with lower risk of HCC (9) . Genotype D is one of the most cosmopolitan genotypes and comprises of ten subgenotypes (D1-D10). Among them, D1-D3 are distributed worldwide while D4-D9 show restricted appearance (21) . But the association of genotype D with HCC is not conclusive yet. Few recent studies have depicted that HBV genotype D is the predominant genotype in India followed by genotype C and A (22, 23) . Six subgenotypes of HBV/D (D1, D2, D3, D4, D5 and D9) have been documented here (24) (25) (26) . HBV-genotype D represents a unique HCC scenario in India, where the burden of LC is fairly high but the prevalence of HCC is relatively low and the detection of HCC is also quite late leading to poor prognosis (9, 26) . Now to comprehend the disparity in the patho-physiological mechanism and the influence of HBV subgenotypes on disease progression and HCC development, this cross sectional study was designed with 121 treatment naïve patients having progressive disease stages from chronic hepatitis to HCC. Using several in vitro assays, we tried to elucidate the contribution of the two main HBV subgenotypes, D1 and D3, circulating in this part of the world, on the progression of chronic liver diseases to HCC.
Materials and methods

Ethics statement
Institutional Ethics Committee of Institute of Post Graduate Medical Education and Research (IPGME&R), Kolkata has approved the study (Inst./ IEC/646). Informed written consents were collected from all the participants included in the study.
Study subjects
Chronic hepatitis B infected patients (carrying HBsAg for >6 months) with different clinical manifestations coming for evaluation in either clinical hepatology services of the School of Digestive and Liver Diseases, IPGME&R, Kolkata (n = 101) or at Centre for Liver and Biliary Sciences, Indraprastha Apollo Hospital, New Delhi (n = 20) and willing to comply with the study protocol were enrolled for detailed virological assessment.
Complete clinical, biochemical, radiological evaluations and virological examinations were performed on each patient as clinically indicated. All patients were treatment naïve/ineligible chronic HBV infected, age above 18 years, negatives for anti-HCV and anti-HIV and having no history of diabetes and alcohol abuse.
Evaluation of liver disease status
For the purpose of categorization of the included patients, every patient underwent liver stiffness measurement in Fibroscan machine. The value of liver stiffness measurement less than 12.5 kPa was taken as CHB without LC and more than 12.5 kPa was considered as cut-off for the diagnosis of cirrhosis (27) . All subjects were subsequently subclassified into three categories (1): 'Chronic hepatitis B' (CHB without LC) (n = 52) was defined histologically, supplemented with endoscopic and radiological evidences of absence of varices and portal hypertension (2); 'liver cirrhosis' (LC) (n = 30) was diagnosed histologically and/or portal hypertension (splenomegaly/ dialeted portal vein with altered flow pattern/ascites etc.), upper GI endoscopic confirmation of gastric varices and/or ultrasonographic reports (3); 'Hepatocellular carcinoma' (HCC) (n = 39) was diagnosed as per standard protocol using ultrasound, spiral/triphasic dynamic CT scan and/or serum alfa-fetoprotein (AFP) levels, apart from histology of explanted tissues. Blood samples were collected from all patients; serum was separated and preserved at −80°C till further use.
Isolation of viral DNA and quantification of viral copy number
HBV DNA was extracted from 200 µl of serum samples using QIAamp DNA Mini Kit (Qiagen Inc., Valencia, CA) following manufacturers' instructions and used to quantify viral copy by real-time PCR using a commercial SYBR Green PCR Master mix (Applied Biosystems, Foster city). The lower limit of detection is 250 copies/ml.
Amplification of FL HBV and DNA sequencing
The FL HBV genome (~3.2 kb) was amplified from serum derived viral DNA with P1/P2 primer set (28) . In case of sample with low viral load, nested PCR was performed using MP1/1017R and 2801F/MP2 primer sets and first round PCR product as template (Supplementary Table 1 , available at Carcinogenesis Online). The QIA Quick PCR Purification Kit (Qiagen, CA) was used to purify amplified products and subjected to sequencing reaction using BigDye terminator v3.1 cycle sequencing kit (ABI, USA) and multiple primers (Supplementary Table 1 , available at Carcinogenesis Online) to cover the FL genome of HBV. After automated DNA sequencing on ABI Prism 3130, each sequence was edited and analysed using Seqscape V2.5 (ABI) software.
Construction of phylogenetic tree
Clustal W (MEGA 4.1) software was used to construct the phylogenetic tree. The FL HBV sequences from 121 samples were compared with 32 representative HBV sequences of eight different genotypes (A-H) retrieved from GenBank. To confirm the reliability of the phylogenetic tree analysis, bootstrap re-sampling and reconstruction were carried out 5000 times. Sequence variability was analysed with the help of multiple sequence alignment tool.
Accession number of submitted nucleotide sequences
The FL genome sequences of 92 chronic HBV patients were used from our previous publications (29) . Twenty-nine new sequences are included in the Genbank http://www.ncbi.nlm.nih.gov/GenBank/index.html by the accession numbers KX196208-KX196236. The FL HBV was amplified and digested with SapI enzyme to get the linear monomeric form of HBV DNA, so that the viral genes are transcribed using its own promoters and enhancers. About 1 μg of DNA was transfected in cell lines seeded in 12 wells plate using either Lipofectamine 2000 (Invitrogen, CA) or X-tremeGENE (Roche, Basel, Switzerland) transfection reagents following manufacturers' protocols. After 72 h of transfection, cells were harvested and either intracellular core particle associated viral DNA, or total RNA and protein were isolated. Each experiment was performed in duplicate and repeated thrice. For Entecavir treatment, media was changed every 24 h.
Cell culture and transfection
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from cell line using TRIzol® reagent (Life Technologies, CA) and then 3 μg of RNA was converted into cDNA using high-capacity cDNA Reverse Transcription kit (Applied Biosystems, CA) following the manufacturers' protocol. Quantitative PCR was performed to analyze the gene expression using gene specific primers (Supplementary Table 1 , available at Carcinogenesis Online) and SYBR® Green PCR Master Mix (Roche Diagnostics, Mannheim, Germany) in ABI Quant studio 7. To normalize each data, 18s rRNA was used as internal control.
Immunoblot analysis
Western blot analysis was performed following standard protocol with mouse anti-γH2aX (Abcam) primary antibody and Goat anti-mouse HRP tagged secondary antibody.
Promoter-luciferase assay
To determine the ER stress after transfection of linear HBV DNA in hepatocyte, promoter activity of GRP78 gene was assayed by Dual-Luciferase Reporter Assay kit (Promega, Madison) in luminometer as described in our previous study (23) and expression levels of resident ER stress markers were quantified by qRT-PCR.
Quantification of cellular reactive oxygen species (ROS)
2′-7′-dichlorofluorescein diacetate (DCFDA) is a non-fluorescent compound and in the presence of ROS, it produces green fluorescent, 2′-7′-dichlorofluorescein (DCF). Immediate prior to use, fresh solution of DCFDA was prepared in sterile DMSO and it was added to the media (20 μM) of HBV transfected HepG2 cells. After 30 min, cells were harvested, washed and suspended in phosphate buffer saline and DCF positive cells were counted in flow cytometer.
Anchorage-independent cell growth assay
HBV DNA transfected HepG2 cells (10 3 cells) in 1× media were mixed with equal volume of 2× complete media containing 20% fetal bovine serum and 0.8% agarose and kept at 42°C for 15 min to equilibrate. It was then plated on top of another layer comprising of 0.6% agarose in complete growth media. Colonies were counted after 15 days.
Invasion assay
Equal number of HepG2 cells were transfected with either linear HBV DNA or control vector and after 30 h of transfection, cells were transferred on top of growth factor reduced matrigel basement matrix (ThermoFisher Scientific) coated upper well of Boyden chamber and number of cells invaded were counted from lower surface after staining with crystal violet at different time intervals. About 30% fetal bovine serum was used in the lower compartment as chemo-attractant. Cells from upper chamber were wiped out before staining of the cells in the lower surface.
In vitro tube formation assay
HUVEC cells (0.5 × 10 4 ) were seeded on 96-well culture plates (Corning, NY) pre-coated with growth factor-reduced matrigel (ThermoFisher Scientific). After 6 h, HUVEC cells were incubated with conditioned media (1:1 ratio) of HBV DNA transfected HepG2 cells and allowed to generate network (ThermoFisher Scientific). Tubules in each field were imaged and an average of tubules from six fields in each well were counted.
Cell viability or cytotoxicity assay
WST1 colorimetric assay kit (Roche Applied science, Germany) was used to quantify cell viability in presence of increasing doses of Entecavir (Sigma-Aldrich) by following manufacturer's protocol.
Statistical analysis
Statistical analyses were performed using SPSS version 16.0 and GraphPad Prism 5. Mann-Whitney U test and χ 2 test or Fisher's exact test were considered for continuous and categorical variables as appropriate. The independent Student t-test or one-way ANOVA was used to compare data between two different groups or within groups. P < 0.05 was considered as statistically significant.
Results
Clinical and demographic characteristics of study subjects
Demographic, clinical and biochemical particulars of patients included in the study are presented in Table 1 . Based on clinical and histopathological assessment, 121 treatment naïve chronic HBsAg positive patients were categorized into three different groups including 52 CHB patients without LC, 30 patients with LC and 39 HCC patients. Out of 121 patients, 85.1% (103/121) were male, 35.9% (37/103) male patients were with HCC and 56.4% (22/39) of the total HCC patients had underlying LC. Except aspartate aminotransferase, international normalized ratio all other clinical parameters were significantly altered across the three groups.
Regional distribution pattern of HBV genotypes and subgenotypes across the progressive liver disease stages
Phylogenetic tree analysis with FL genome sequences of chronic HBV patients (n = 121) revealed that the three distinct HBV genotypes, A, C and D were present in this studied population, which is similar to the earlier reports from Eastern India (Supplementary Figure 1 , available at Carcinogenesis Online) (29) . Among 121 patients, 80% (n = 97) of the patients were clustered to genotype D whereas only 12% (14/121) and 8% (10/121) had C and A genotype respectively (Table 1) . Again, 90% (9/10) sequences of A genotype were classified as subgenotype A1 and 10% (1/10) as A2 whereas 21% (3/14) and 79% (11/14) of HBV/C genotypes were matched to C1 and C2 subgenotype, respectively. Among genotype D sequences, 48% (47/97) and 42% (41/97) belong to subgenotype D1 and D3 while only 3% (3/97) and 6 % (6/97) clustered to D2 and D5, respectively. Interestingly, a significant difference was observed in the distribution pattern of subgenotype D1 and D3 in patients with HCC [51% (20/29) and 18% (7/29)] (P < 0.001) and LC [37% (11/27) and 53% (16/27)] (P < 0.05) ( Table 1) . Thus a decreasing trend in frequency of D3 was observed from LC to HCC (59%, 16/27 to 26%, 7/27) (P < 0.01), in contrast the frequency of D1 was noted significantly higher in HCC (74%, 20/27) compared to LC (41%, 11/27) (P < 0.01) (Figure 1 ). Among HBV/D1 infected HCC patients, 80% (16/20) patients were with underlying cirrhosis (Table 2) implicating HBV/D1 infected LC patients are at high risk for the development of HCC. , P = 0.04), no significant difference was observed when biochemical parameters were compared between D1 and D3 carrying patients (Table 2) . To comprehend the impact of the two major subgenotypes of HBV/D1 and HBV/ D3 on the pathogenesis of HCC various complementary in vitro experiments were performed.
Contribution of HBV subgenotypes on the progression of liver diseases to HCC
Impact of HBV subgenotypes on the in vitro replication of the virus
The replication efficiency of the two HBV genomes were compared after transfection of SapI digested linearized monomeric viral genome in HepG2 cells and subgenotype C2 was included as positive risk factor for HCC. After 72 h of transfection, viral DNA was quantified from the intracellular core particle and the culture supernatant by real time PCR. As shown in Figure 2a , the HBV DNA level was about 2.5-fold higher in HBV/D1 than HBV/D3 in both the cases. In concordance with this data, the amount of secreted HBsAg level was also noted 1.5-fold more in D1 than D3, whereas there was no significant difference in the pregenomic RNA levels between these two subgenotypes. This data also supports the higher viral load found in patients infected with HBV/D1 than HBV/D3 indicating HBV might have subgenotype specific replication efficacy and disease correlation (Table 2) . Interestingly, the replication efficiency of subgenotype C2 was found about 1.8-fold more to that of subgenotype D1 (Figure 2a ). The expression of viral oncogene HBx was also noted significantly higher in HBV-subgenotype D1 (4-fold) and C2 (6-fold) than D3 (Figure 2a) .
Comparison of drug sensitivity of HBV/D1 and HBV/D3 in in vitro assay
Nucleoside and nucleotide homologs are used commonly to suppress viral replication and to halt progression of liver diseases. In the current study, treatment naïve chronic HBV-infected patients were included. Therefore, to correlate the effect of drug and viral subgenotypes, an in vitro drug sensitivity assay was performed with increasing doses of entecavir (1,10, 25 and 50 nmol/ml) for 3 days in HBV/D1, D3 and C2 transfected HepG2 cells and secreted HBsAg level was quantified. At these concentrations, entecavir showed no cytotoxicity to HepG2 cells (Figure 2b ) but secretion of HBsAg was dropped dose dependently more in HBV/D1 than D3 and C2 indicating HBV/D1 might be more sensitive to entecavir than HBV/D3 (Figure 2c ). But the current therapy with anti-viral drug rarely achieves a complete cure due to persistence of intrahepatic viral covalently closed circular (ccc) DNA. Thus, considering our clinical and preliminary in vitro data, neoplastic transformation efficiency of the two HBV subgenotypes was further compared in the subsequent in vitro experiments.
Comparison of anchorage independent growth (AIG) and migration of HBV/D1 and HBV/D3 transfected cells
Anoikis (cell detachment induced apoptosis) resistance and anchorage independency are the crucial steps in the acquisition of malignancy. Thus we first tested anchorage independent cellular growth of HBV/D1 and D3 transfected HepG2 cells. Cells were transfected with linearized HBV/D1 and D3 DNA independently and allow to grow on soft agar bed. HBV/C2 DNA was considered as positive control for HCC development. After 15 days of transfection, we found 1.8-fold more number of colonies in HBV/D1 than HBV/D3 transfected cells (Figure 3a) , whereas HBV/ C2 showed 1.2-fold more colonies than HBV/D1. Again, cells those loose anchorage dependency easily migrate through body fluids to other organ (30) . A preliminary in vitro scratch assay or wound healing assay in HepG2 cells transfected with two HBV DNA separately showed that HBV/D1 could migrate faster than HBV/D3 cells (Figure 3b ) and the data of HBV/D1 was more close to HBV/C2 than HBV/D3 (Figure 3b) .
Comparison of invasion and angiogenic potential of HCC cells infected with HBV/D1 and HBV/D3
Now invasion and angiogenesis are two indispensible components for sustaining growth of tumor cells. Invasion efficiency of HepG2 cells transfected with either HBV/D1 or HBV/D3 through matrigel coated bed was compared using Boyden chamber and as expected number of HBV/D1 transfected cells migrated to the lower surface of the membrane was significantly higher than HBV/D3 (Figure 3c ). Furthermore, in vitro tube formation assay with endothelial cells (HUVEC) seeded on growth factor reduced matrigel bed revealed that larger number of intact capillary like structures were generated when cells were incubated with the conditioned media of HBV/D1 transfected HepG2 cells than HBV/ D3, which generated distorted tubular like structures (Figure 3d ). Higher level of expression of vascular endothelial growth factor (VEGF), which is the key regulator of physiological and pathological angiogenesis in HBV/D1 transfected hepatocytes compared to HBV/D3 also suggested that HBV/D1 has more tumor promoting pro-angiogenic potential than HBV/D3 (Figure 3e) . Now epithelial-mesenchymal transition (EMT) is the prerequisite step for losing cellular polarity and gaining of invasiveness and metastatic properties. Thus expression of mesenchymal markers N-cadherin, SNAIL2 and TWIST were verified in HBV/D1 and D3 transfected cell lines. All the three genes were noticed significantly overexpressed in HBV/D1 transfected cell lines compared to HBV/D3 (Figure 3f ).
Enhanced viral replication induces genomic instabilities through higher endoplasmic reticulum (ER) stress and oxidative DNA damages
Now to investigate the impact of HBV subgenotypes, D1 and D3, on the mechanism of HBV-mediated oncogenesis, viral replication induced endoplasmic reticulum (ER) stress, oxidative DNA damages etc. were compared.
During productive HBV replication, large amount of unfolded viral proteins are accumulated in the ER and perturbs the normal function of it. To counteract this stress, ER induces unfolded protein response pathways, which includes activation of two sensory kinases IRE1 and PERK and translocation of transcription factor ATF6 in golgi bodies upon dissociation of ER chaperon GRP78 (31) . These lead to release of stored Ca 2+ from ER, which may generate reactive oxygen species (ROS) in mitochondria, perturb mitochondrial membrane potential and cause oxidative DNA damages (32) . Thus, to corroborate with the high replication capacity of HBV/D1, unfolded protein response in ER was measured first by quantifying the promoter activity of GRP78 after co-transfection of either HBV/D1 or HBV/D3 viral DNA with pGL3-GRP78-Luciferase construct in HepG2 cells. The luciferase activity of GRP78 was recorded 1.5-fold higher in presence of HBV/D1 than HBV/ D3 (P < 0.001, Figure 4a) . Subsequently, the relative expression of GRP78, ATF6, IRE1 and PERK1 were also noted significantly elevated in presence of HBV/D1 compared to HBV/D3 (Figure 4b) .
Again, integration of HBV DNA into host genome is increased with ROS production, as it generates single and double strand DNA breaks (33) . Thus, the amount of accumulated ROS and double strand DNA breaks were quantified in HBV/D1 and HBV/ D3 transfected cells. Both the conversion of DCFDA to DCF as measured in flow cytometer and γH2AX band intensity detected in western blot analysis were found to increase significantly in HBV/D1 transfected cells compared to HBV/D3 (Figure 4c and d) . Cumulatively, these data suggest that similar to infection with HBV subgenotype C2, HBV/D1 is associated with more severe liver damages than HBV/D3. Hence, CHB patients infected with HBV/D1 are more susceptible to develop aggressive HCC than patients infected with HBV/D3.
Discussion
With molecular and complementary mechanistic insights, this study has demonstrated that clinical manifestation of CHB infection is not limited to the host factors; it is largely contributed by the viral factors including HBV genotypes and subgenotypes. The influence of HBV genotypes on liver disease progression has been studied extensively but restricted geographic distribution of myriads of HBV subgenotypes restrained the comparative analysis among subgenotypes with liver disease progression. So far, the majority of the studies have discussed the association of most prevalent genotypes such as HBV/B and HBV/C and their subgenotypes B1 and C1, C2 with the disease from epidemiological data (9, 12) . Despite ubiquitous distribution of HBV/D in Europe and India, the impact of 10 HBV/D-subgenotypes on disease outcome is not conclusive yet. Only one Indian epidemiological study has documented that HBV/D1 is significantly associated with chronic liver diseases and D3 with occult HBV infection (34) . For the first time, this study has been executed on patients with clinically and/or histologically defined complete range of progressive liver disease stages including CHB, LC and HCC from same geoethnic background and showed that HBV/ D1 infection is associated more with the progression of liver diseases towards HCC than HBV/D3, which was noted high in cirrhosis. In addition, evidences from complementary in vitro assays have supported the epidemiological data and disclosed that compared to HBV/D3, HBV/D1 replicated faster and triggered more ER stress. This leads to accumulation of ROS, intracellular oxidative DNA damages and enhancement of cellular proliferation, migration, invasion and angiogenesis. Thus, these novel findings delineate the influence of HBV/D subgenotypes on the pathogenesis of the disease and its influence on the clinical outcomes.
A systematic study to determine the distribution pattern of genotype and subgenotype of HBV during progressive liver disease stages including CHB, LC and HCC revealed that genotype D predominates in India followed by genotype C and A which is similar to the earlier observations (23) (24) (25) (26) 29) . But, among ten subgenotypes of HBV/D, D1 (49%) and D3 (42%) were found two prevalent subgenotypes circulating in Eastern India followed by D2 (3%) and D5 (6%) among the studied groups. This data is little contradictory to the previous report from the same region where the study was restricted to HBsAg positive CHB and asymptomatic patients along with the occult HBV infection and observed 34%, 29%, 20% and 17% of D3, D2, D5 and D1, respectively (35) . Interestingly, in our study the frequency of HBV/D1 was increased with advancement of liver diseases from CHB (31%) to HCC (51%) through LC (37%) whereas that of HBV/D3 decreased significantly in HCC (18%) from LC (53%) implicating HBV/D1 infected patients are at high risk for the development of HCC. This result almost coincides with an African study where A1 subgenotype had 4.5-fold increased risk of developing HCC than non-A genotype (36) and a study from China depicted the association of subgenotype C2 with LC and HCC while subgenotype B2 with CHB (19) . A study from Japan showed that subgenotype B2 causes more cellular damages than B1, A1 and A2 (37) . Thus infection with HBV/A1/B2/C2/D1 subgenotypes might have higher oncogenic potential irrespective of the host ethnicity.
Of particular note, a North Indian study reported that HBV/D genotype predict the occurrence of HCC in young patients less than 40 years, while recently we have reported the association of genotype D with late age HCC (29, 35) . This discrepancy may be due to circulation of two different subgenotypes of HBV/D in East and North India. We have observed that patients included in this study had comparable age, HBeAg positivity, alanine aminotransferase levels etc. but distribution of HBV subgenotypes varies with the disease stages such as HCC patients were infected more with HBV/D1 while cirrhotic patients with HBV/D3. Again, the age of D1 infected patients were observed significantly low in CHB compared to D3 but it was not followed with disease progression. Now, the accumulation of mutations in the replicating viral genome during progression of liver diseases might be one of the reasons of subgenotype specific disease outcome. Thus, the frequency of recently reported genotype D specific HCC associated mutations (A1762T/G1764A, C1653T, T1753V and their combinations) was investigated (unpublished data) (29) and observed that those mutations have almost no connection to subgenotypic effect on disease consequences. Thus to comprehend the clinical significance of HBV subgenotypes on the progression of liver diseases, several in vitro functional assays were performed.
HBx is the smallest HBV protein and is considered as multifunctional oncoprotein. Studies on HBx oncogenicity in transgenic mice yielded divergent results due to difference in mice genotypes, but majority of the data suggested that transgenic expression of HBx is associated with oncogenic transformation of hepatocytes (38) . In our study, over expression of HBx and multiple EMT markers along with enhanced anchorage independent growth, migration, invasion and angiogenesis in HBV/D1 transfected cells indicated that HBV/D1 has higher oncogenic potential than HBV/D3. The viral oncoprotein HBx is also a positive regulator of proangiogenic factor VEGFA (39) and transcription factor NF-κβ (40) . On the other hand, activation of TNF-α/TRADD mediated caspase8/caspase3 dependent intrinsic apoptosis pathway and expression of fibrotic genes (collagen I, TGFβ) were noted higher in HBV/D3 than D1 (unpublished data). It is well established that dead hepatocytes are engulfed by either hepatic Kupffer cells, which trigger TRAIL, FAS, TNFα in a feed-forward loop for apoptosis or hepatic Stellate cells which induces myofibroblast transformation and secretion of collagen I, TGFβ etc. and thus promoting fibrosis and cirrhosis (41) .
It is well documented that ER is the site of assembly and maturation of virion particles and HBV proteins in the ER induces stress. Hence, deposition of excess unfolded or misfolded proteins in ER is directly linked with viral replication (31) . To circumvent this stress, cellular unfolded protein response pathways get activated. Upon activation of chaperon protein GRP78, other ER transmembrane signaling proteins such as PERK1, IRE1 and ATF6 are released. Under prolonged stressed condition, this causes generation of ROS and DNA damages (42, 43) , which either triggers apoptosis or activates autophagy to degrade unfolded proteins to maintain ER integrity and cell viability (44, 45) . Higher expression of autophagy markers such as BECLIN 1 and ATG5 in HBV/D1 transfected cells than HBV/ D3 (unpublished data) suggesting HBV/D1 cells activate autophagy in response to the high intracellular ER stress and accumulated ROS, which enables tumor cell proliferation and growth. Deregulation of cell cycle checkpoint protein p16 also supports the abandoned cell proliferation (unpublished data) in HBV/D1 transfected cells. Now nucleoside and nucleotide analog (NA) therapy is obligatory for eligible CHB patients according to the guidelines. NAs (Entecavir, Tenofovir) can reduce viremia by 5-6 logs with low rate of resistance, but anti-viral therapy rarely cures the virus completely because of refractory nature of HBV replicative intermediate termed cccDNA (46) . Hence, virus can rebound upon therapy withdrawal or immune-suppression. Along with this drawbacks in the therapy, few groups have documented that rate of therapy resistance varies with viral genotypes and subgenotypes. HBV/D is found to be more sensitive to Lamivudine than HBV/A (47) whereas few studies from Southeast Asia showed genotype C is less susceptible to Lamivudine over genotype B (48) and opposite data is reported from USA (49). Li Xiaodong et al. has documented that HBV/C2 is more resistant to Lamivudine than HBV/B2 whereas no obvious difference was seen in occurrence of Adefovir and entecavir resistant mutations (50) suggesting HBV subgenotypes might have impact on drug resistance. Our study suggests that HBV/D1 is more sensitive to Entecavir therapy than HBV/D3 in in vitro setting. Further advancement in knowledge is required to clarify the impact of the HBV subgenotypes and drug-resistant mutational patterns on the antiviral response and disease progression, which could be useful in clinical practice.
Thus, this epidemiological and complementary in vitro study suggests that severity and prognosis of liver diseases are indispensible to HBV subgenotypes. Patients infected with HBV/D1 subgenotype might be more susceptible to severe liver damages followed by rapid progression towards HCC than HBV/D3 subgenotype. Although the mechanism needs to be sought by which subgenotype D1 causes more DNA replication, but our results clearly describe that hepatitis B research should concentrate on viral subgenotype together with host and environmental factors to generate a better effective therapeutic. For the first time this study is reporting the functional association of HBV/D subgenotypes with the progression and pathogenesis of liver diseases. Hence, these novel findings highlight the importance of determination of HBV subgenotypes and requirement of life-long periodic monitoring of chronic HBV patients, which is important for better management of HCC patients with early disease stages when curative therapy could be offered.
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